Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $1,601,104.12 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 50,716 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $31.57, for a total transaction of $1,601,104.12. Following the completion of the sale, the chief operating officer now directly owns 216,286 shares of the company’s stock, valued at approximately $6,828,149.02. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.15, for a total transaction of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.18, for a total transaction of $281,800.00.
• On Tuesday, September 10th, Jonathan Young sold 568 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total transaction of $14,870.24.

Akero Therapeutics Price Performance

Shares of NASDAQ:AKRO traded down $0.50 during trading on Tuesday, hitting $31.55. 7,638 shares of the company’s stock were exchanged, compared to its average volume of 869,998. Akero Therapeutics, Inc. has a 1-year low of $13.39 and a 1-year high of $37.00. The firm has a 50-day moving average price of $28.42 and a two-hundred day moving average price of $24.89. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. As a group, analysts expect that Akero Therapeutics, Inc. will post -3.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Tuesday, September 17th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Akero Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its stake in shares of Akero Therapeutics by 2,366.0% in the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after acquiring an additional 1,183 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Akero Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after acquiring an additional 446 shares in the last quarter. Eastern Bank bought a new stake in Akero Therapeutics during the third quarter worth about $100,000. Headlands Technologies LLC lifted its position in Akero Therapeutics by 253.5% during the first quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock worth $107,000 after purchasing an additional 3,024 shares during the period. Finally, Ameritas Investment Partners Inc. lifted its position in Akero Therapeutics by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after purchasing an additional 1,030 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.